Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.090
-0.030 (-0.96%)
May 14, 2025, 1:33 PM - Market open
Company Description
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery.
It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease.
It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Regina Graul |
Contact Details
Address: 245 First Street, Riverview II, 18th Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 857 327 8778 |
| Website | cyclerion.com |
Stock Details
| Ticker Symbol | CYCN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001755237 |
| CUSIP Number | 23255M105 |
| ISIN Number | US23255M2044 |
| Employer ID | 83-1895370 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Regina M. Graul Ph.D. | Chief Executive Officer, President and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | 8-K | Current Report |
| May 7, 2025 | 424B5 | Filing |
| May 6, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 6, 2025 | 10-Q | Quarterly Report |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2025 | SCHEDULE 13D/A | Filing |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 10-K | Annual Report |
| Feb 12, 2025 | EFFECT | Notice of Effectiveness |